Statin Use in Hospitalized Patients with COVID-19: A Comprehensive Analysis of the New York City Public Hospital System

Li, Weijia; Rios, Saul; Nagraj, Sanjana; Hajra, Adrija; Saralidze, Tinatin; Varrias, Dimitrios; Mathai, Sheetal Vasundara; Novakovic, Marko; Hupart, Kenneth H.; Miles, Jeremy; Katamreddy, Adarsh; Palaiodimos, Leonidas; Faillace, Robert T.

doi:10.1016/j.amjmed.2022.02.018

Cited by 4 publications

(4 citation statements)

References 60 publications

(74 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In 2021, an observational study by Belgian investigators reported that inpatient statin treatment was associated with reduced COVID-19 mortality [ 26 ]. At least 24 observational studies have reported similar results [ 26 , 158 , 169 , 182 , 183 , 184 , 185 , 186 , 187 , 188 , 189 , 190 , 191 , 192 , 193 , 194 , 195 , 196 , 197 , 198 ]. The results of six RCTs of inpatient statin treatment have also been reported [ 199 , 200 , 201 , 202 , 203 , 204 ].…”

Section: Inpatient Statin Treatmentmentioning

confidence: 89%

“…Of the 22 observational studies of inpatient statin treatment, 12 used propensity score matching to minimize confounding [ 26 , 158 , 182 , 185 , 187 , 189 , 191 , 193 , 194 , 196 , 197 , 205 ], five reported treating >1000 patients [ 170 , 182 , 184 , 189 , 197 ], and many of the remaining studies included hundreds of subjects. All but one observational study [ 194 ] showed that statins significantly reduced COVID-19 mortality.…”

Section: Inpatient Statin Treatmentmentioning

confidence: 99%

See 1 more Smart Citation

Treating COVID-19: Targeting the Host Response, Not the Virus

Fedson¹

2023

Life

View full text Add to dashboard Cite

In low- and middle-income countries (LMICs), inexpensive generic drugs like statins, ACE inhibitors, and ARBs, especially if used in combination, might be the only practical way to save the lives of patients with severe COVID-19. These drugs will already be available in all countries on the first pandemic day. Because they target the host response to infection instead of the virus, they could be used to save lives during any pandemic. Observational studies show that inpatient statin treatment reduces 28–30-day mortality but randomized controlled trials have failed to show this benefit. Combination treatment has been tested for antivirals and dexamethasone but, with the exception of one observational study in Belgium, not for inexpensive generic drugs. Future pandemic research must include testing combination generic drug treatments that could be used in LMICs.

show abstract

Section: Inpatient Statin Treatmentmentioning

confidence: 89%

Section: Inpatient Statin Treatmentmentioning

confidence: 99%

Treating COVID-19: Targeting the Host Response, Not the Virus

Fedson¹

2023

Life

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

“…Many other studies showed that the use of statins has been shown to be linked with lower mortality rates and improved outcomes for COVID-19 patients, which is in disagreement with the results. [32][33][34][35][36][37][38] Study limitations. The retrospective nature of the study, which introduces the possibility of inaccurate data being recorded in the patients' files or inadvertently misrepresented in the data file.…”

mentioning

confidence: 99%

Statin use and clinical outcomes in hospitalized COVID-19 patients

Alshaalan,

Alkahtani,

Althobaiti

et al. 2024

SMJ

View full text Add to dashboard Cite

Objectives: To investigate the relationship between statin use and coronavirus disease-19 (COVID-19) severity. Methods: This was a retrospective study of adult patients with confirmed COVID-19 who were hospitalized at Prince Mohammed Bin Abdulaziz Hospital, Riyadh, Saudi Arabia. The study was carried out from July - September 2020. Antecedent statin use was evaluated using medication information available in the electronic medical records. Results: In this retrospective study, we collected data from 689 patients hospitalized with COVID-19. Among the patients, 56.2% of them were non-Saudi and 67.3% were males. The mean age of the patients was 53.7 years. The most common comorbidities among patients with COVID-19 at admission were hypertension (65.2%) and diabetes mellitus (65%). Among these patients, 155 (22.5%) patients received statins during hospitalization and 79.7% of them received corticosteroids. Receiving statins significantly increased the risk of intensive care unit’s admission by 1.64 times, intubation by 1.76 times, developing complications by 2.48 times, and mortality by 3.16 times. Conclusion: Statins are associated with a higher risk of mortality and morbidity among patients hospitalized for COVID-19.

show abstract